{
    "Trade/Device Name(s)": [
        "LIAISON VZV IgG HT",
        "LIAISON Control VZV IgG HT",
        "LIAISON\u00ae VZV IgG HT",
        "LIAISON\u00ae Control VZV IgG HT"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K231214",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150375"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFY"
    ],
    "Summary Letter Date": "October 27, 2023",
    "Summary Letter Received Date": "September 29, 2023",
    "Submission Date": "October 27, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.3900",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Varicella-zoster virus serological reagents",
        "Quality Control Material"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "chemistry"
    ],
    "Analyte(s)": [
        "IgG antibodies to varicella-zoster virus"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum (with gel and without gel-SST)",
        "Dipotassium EDTA (K2-EDTA)",
        "Lithium heparin",
        "Sodium heparin"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON XL Analyzer",
        "DiaSorin LIAISON analyzer family"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON VZV IgG HT chemiluminescent immunoassay and control for qualitative detection of VZV IgG in serum and plasma.",
    "Indications for Use Summary": "Aids in the determination of previous varicella-zoster virus infection by detecting specific IgG antibodies in human serum and plasma; for use with LIAISON XL Analyzer.",
    "fda_folder": "Microbiology"
}